Clinical trials: Neoplasms, Hematologic
Multiple Myeloma, Renal Impairment
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
This is an Investigator-Initiated, phase 2, prospective, open-label study designed to be conducted in six hospitals in Greece. Eligible patients will initially receive an induction phase of six 28-day cycles of isatuximab in…
- Conditions
- Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type
- Trial name
- NCT05147493
- Testing
- Isatuximab, Bortezomib, Cyclophosphamide
- Where
- 6 sites in Greece
- Volunteers
- 51 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma, Renal Impairment
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
This is an investigator-initiated (IIS), phase 2, prospective, open-label, multinational study, designed to be conducted in approximately 14 sites.
- Conditions
- Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type
- Trial name
- NCT05298683
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 6 sites in Greece
- Volunteers
- 108 people
- Sponsor
- Hellenic Society of Hematology
Sarcopenia, Pediatric Cancer
Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
In children, both malnutrition and sarcopenia are associated with prolongation of hospital stay, increased morbidity, mortality, and health-related complications.
- Trial name
- NCT05294380
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Trakya University
Myeloproliferative Disorders, Lymphoproliferative Disorders
In Vitro Drug Sensitivity Testing of Fresh Human Samples
Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid…
- Trial name
- ESAAC (NCT05001386)
- Testing
- Blood collection for the evaluation of the anti-drugs sensitivity
- Where
- 2 sites in France
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Hematologic Malignancy
Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation
This phase I/II study the side effects and efficacy of natural killer cells after donor stem cell transplant and how they treat patients with myeloid malignancies or lymphoproliferative disorders.
- Trial name
- NCT05250362
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sichuan University
Haematological Malignancy, Acute Leukemia
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts
To date, allogeneic haematopoietic stem cell transplantation (aHSCT) is the only curative treatment for many paediatric and young adult haematological pathologies (acute leukaemia, myelodysplastic syndromes, haemoglobinopathies…
- Conditions
- Haematological Malignancy, Acute Leukemia, Myelodysplastic Syndromes, Hemoglobinopathy in Children
- Trial name
- EVAADE (NCT04331483)
- Testing
- Physical activity program
- Where
- France
- Sponsor
- Centre Leon Berard
Hematologic Cancer
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
The purpose of this study is to perform a prospective study that is histology-independent personalized navigation approach to cancer therapy based upon tumor molecular profile as determined by Clinical Laboratory Improvement…
- Trial name
- I-PREDICT Heme (NCT03955276)
- Testing
- Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of California, San Diego
Hematologic Neoplasms
Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy
This study is aimed to determine the feasibility of obtaining and molecularly characterizing pre-treatment tumor biopsies, to determine the feasibility of obtaining and molecularly characterizing archival and post-treatment tumor…
- Trial name
- NCT01869218
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
Multiple Myeloma
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, and identify the recommended doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients with relapsed and/or refractory multiple…
- Trial name
- NCT03111992
- Testing
- PDR001, CJM112, LCL161
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Diarrhea
Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients
Diarrhea is a common problem in the pediatric population. Children with cancer are especially at increased risk for gastrointestinal infection-related morbidity and mortality due to their ongoing immunosuppression.
- Trial name
- NCT02464098
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- St. Jude Children's Research Hospital
Multiple Myeloma, Lymphoma
Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease
Background: Family caregivers are of great importance to patients undergoing treatment for cancer, but at the same time, caregivers themselves are in great risk of distress and high symptom burden which affects their quality of…
- Conditions
- Multiple Myeloma, Lymphoma, Bone Marrow Transplantation, Neoplasms
- Trial name
- NCT04039100
- Testing
- Family Caregiver Ambassador Support
- Where
- Denmark
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Covid19, Myeloma Multiple
Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden
This retrospective observational cohort study aims to describe the impact of COVID-19 in patients treated with autologous stem cell transplantation (ASCT) for malignant disease in terms of risk factors, morbidity, need for…
- Conditions
- Covid19, Myeloma Multiple, Malignant Lymphoma, Hematologic Neoplasms
- Trial name
- AutoCOVID-19 (NCT04760184)
- Testing
- Autologous stem cell transplantation
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Uppsala University
Multiple Myeloma
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor…
- Trial name
- NCT03875495
- Testing
- Temferon
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Genenta Science
Hematological Malignancies
Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
The present project aims at comparing two nonmyeloablative regimens currently used in 2 major HCT centers in the US for patients with HLA-matched related or unrelated donor: the one from the Seattle group consisting of 2 Gy TBI…
- Trial name
- NCT00603954
- Testing
- Conditioning regimen: TBI + Fludarabine, Conditioning regimen:TLI (8 Gy) + ATG
- Where
- 11 sites in Belgium, Netherlands
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Liege
Hematologic Malignancies
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.
- Trial name
- NCT04538599
- Testing
- RD13-01 cell infusion
- Where
- China
- Volunteers
- 12 people
- Sponsor
- He Huang
Haematological Malignancy, Leukemia
Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies
The THERMAL study is a pilot study to determine feasibility of using two separate continuous skin temperature monitors during intensive treatment for haematological malignancies.
- Conditions
- Haematological Malignancy, Leukemia, Lymphoma, Myeloma
- Trial name
- THERMAL (NCT05203809)
- Testing
- TempTraq temperature monitor
- Where
- New Zealand
- Volunteers
- 20 people
- Sponsor
- Malaghan Institute of Medical Research
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study
This study determines how the threat of the coronavirus has affected the mental health and physical well-being of cancer patients seen at the psychiatric oncology clinic, and how they have coped with any related stress.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04652505
- Testing
- Questionnaire Administration
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Neoplasms, COVID-19 Vaccines
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
The study will evaluate the immunogenicity, safety and efficacy of vaccines against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) in oncohematological patient population and compare the results with patients…
- Trial name
- NCT04871165
- Testing
- S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests, Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC), Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
- Where
- Lithuania
- Volunteers
- 3,270 people, healthy volunteers welcome
- Sponsor
- Vilnius University
Graft Versus Host Disease, Hematologic Malignancy
Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis
This is a two arm open label phase III clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from any donor are eligible for the study if they meet the standard criteria defined in the…
- Conditions
- Graft Versus Host Disease, Hematologic Malignancy, Cyclophosphamide Adverse Reaction
- Trial name
- CY25 (NCT05158608)
- Testing
- Post-transplantation Cyclophosphamide at dose 25 mg/kg/day, Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
- Volunteers
- 100 people
- Sponsor
- National Research Center for Hematology, Russia
Advanced Solid Tumor or Hematologic Tumor
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets
This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3454 tablets in subjects with advanced solid tumor or hematologic tumor.
- Trial name
- NCT04481607
- Testing
- TQB3454
- Where
- 5 sites in China
- Volunteers
- 96 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.